T he a im of th is art icle is to review th e cur re nt sta te of pha rm acological trea tment of d eliriu m in th e pedi at ric popu lat ion and to derive a treatm ent protocol from our review. The re is a conspicuous lack of res earch in th is area a nd th ere a re no pr evio us reviews in th e lit e ra tu re. To com ple te our obj ecti ve, we pr esent th e cur re n t st a te of treatm ent of de lirium in adults , along with th e limit ed a mo u nt of lit eratu re pertaining to delirium in child re n and adolesce n ts . For referen ce, curre nt ped ia tric pharmacolo gical dosing regim en s a re present ed . Our protocol is d eri ved fro m an ex t ra pola t io n of g uid e lin es for ad ult trea tm ent m esh ed with th e cu rre n t kn owledge pr esent ed in th e lit erat ure pertaining to child re n a nd ad olescents. 25 D elirium is a transi ent m ent al synd ro me of ac u te onse t, charact erized by global impairm ent of cog nit ive fun ct ion s, a re d uced level of consciousness, att entional abnormaliti es, changes in psych omotor ac t ivity a nd a di sord er ed sleep-wake cycle (I ). Th e co nce p t of d elirium has be en recogni zed for a p proximate ly 2500 years (2) . Th e di agnostic crite r ia hav e evo lved to several co re featu r es (Table 1) coupl ed with specifie rs th at distinguish e t iology, i.e. du e to a general medica l condition, du e to multipl e e t iolog ies, for s ubstance in tox icat ion, for s u bstance withdrawal and ca use s not oth e rwise specifie d (3) .
The ave rage preval en ce of d eliriu m in t he ge ne ra l hos pi tal popu lation is 20% (4 ). Althou gh the pediatric popul a ti on ha s no t be en we ll stud ied , Antoon e t a l. (5) r eport ed that a pp ro x imate ly 14% of hospit ali zed b urn pat ients had d elirium . These es t imates m ay be low give n th at t he re is a hi g h rate of m isdiagnosis with d elirium. Arm stron g e t a I., (6) r ep ort ed t hat 46% of hospit ali zed adu lts with d e lirium were mi sdi agn osed , i.e, a d eliriou s pati ent wa s di a gn osed wit h anot her condition (de p ressive di sorder, psychotic di sord er , no diagnosis, etc.). Also th e exp re ssio n of d elirium in child re n can vary from adult s, e.g. magical thinking, mania or reg ression (7) , making the di a gnosis eve n m ore difficult for the treati ng p hys icia ns . T he t ransi ent nature of d elirium a lso ad ds to the difficulty wi th di a gnosis.
The co nseq ue nces of a ltered co nsc io usness can be q ui te d el et erious to th e pati ent, e.g. pulling ou t ca t he te rs a nd ot he r se lf-inj urious be havior and ha s been sho wn in ad ult populations to increase mor tality (4 ,8) . Th us, ea r ly recognition of th e de lir iu m with a pprop ria te treatm ent is esse n tial.
Th e fir st ste p in t he treatm ent of d eli riu m is to id e nti fy any ca us a l cond it ion. Th e mo st co m mo n ca uses involv e intox ication wit h exogenous substances, syst emic or ce re b ral di sease a nd wit hd ra wa l from su bstances of a b use ( I) . H oweve r th e underlyin g e tio logy may not be eas ily di sti ngu ish ed . T his ca n be q uite difficult in that th e d eli riu m may be ca used by multiple e tiolog ies a nd ind ividu all y may not be co nside re d sig nifica n t by th e treatin g ph ysicians. In t he int eri m of di agn osti c work-up, treatm ent sho uld in clude rea ssurance a nd reo ri ent ation. If thi s is not su ffici ent, pharmaco logica l int ervention is used as a n adj u nc t for sym p tom management and antipsychotic m ed ication ha s been th e m a in st ay of treatm e nt (9) . 
Diagno stic Criteria for Delirium
A) Disturbance of consciousness (i.e., reduced clar ity of awar en ess of the environment) with reduced abilit y to focus, susta in, or shift atte ntio n. B) A cha nge in cognition (such as memory deficit , disorientat ion, language disturbance) or th e developm ent of a perceptual disturb an ce that is not bett er accounte d for by a pr eexist ing condition, established, or evolving dementia. C) Th e disturbance develops over a short period of time (usua lly hours to days) and tend s to l1uctu at e during the course of th e day. H al op e rid ol, a bu tyrophe no ne neuroleptic t hat can be adm in ist er ed via e n teral, intram usc u lar or intravenous rou tes, is a well-docum ented safe treatment of deliriu m symptoms in adu lts (9) . It is a high pot ency neuroleptic with low pot ential for anticholin ergic , antialpha-adrenergic a nd autonomic effec ts and is unlikely to exacerbate d elirium (9, 10) . It all eviates ag gr ession, psych om ot or ag ita tion, halluci nat ions a nd delusions (10) and is cons ide re d th e preferred age nt for treating deli ri um in t he cr itica lly ill adu lt (II) . The intravenous rout e has a sa fe side -e ffect profil e a nd has a reduced incid en ce of ex trapyram idal rea cti ons wh en co m pa re d to ora l ad m inistration ( 10, 12) . Th e intravenous rout e is also th e quickest way to initiat e treatm ent, i.e. peak se rum levels are reach ed soon aft er ad m in ist ra tion, wh ereas th e e n te ra l a nd 1M rou tes may take up to several hours ( 10) . Also , parental dos es of hal op eridol have 100% bioavailabi lity (compared to th e approxim at e 60% bioavailabil ity of oral dosing) , and are dos ed a pp roxima te ly one-ha lf that of ora l doses ( 10) . Initi al bolus intraven ou s dos es range from 0.5 to 20 mg (4) a nd mega-d oses (> 1000 mg/day) hav e been given safely in cases of refract ory delirium ( 13, 14) . Specific gu ide lines for treating th e d elirious adu lt patient vary in th e lit e rature. Sha piro et a l. ( I I) out line a sta rting do se of 2 to 10 mg intraven ou sly with th e dosage rep eat ed every 2 to 4 hI'S. Maint enance dosing regimen s have been propo sed of con tin uing int raven ou s halope ridol at 50% of th e do se th at co nt ro lled sym pto ms wit h rapid dose re d uction ( 15) or adm iniste ring low do se (0.5 to 3 mg) ora l ha lop eridol ( 16) .
Antipsychotic medi cations though com mon ly pr escribed to child re n a rc not as well investigat ed. The Food a nd Drug Administration (FDA) ad vertisin g guide lin es for halope ridol indi cat e use in (i) m an agem ent of psych osis, (ii) co ntro l of tics and voca l utt eran ce in T ourette's disorder, (iii) seve re behavioral p robl e ms in chi ldr en marked by combativen ess a nd/or explosive hyperex cit abl e beh avior (tha t is not accou n ta ble to imm ediate provication s) a nd sho rt-te rm treat m ent of ADH D (17) . The lower age limit is 3 yea rs wit h dose limits of 0. 15 rug/kg/day for psychosis and 0.075 rug/k g/d ay for beh avior di sorde rs an d T ourett e's disorde r ( 17) . Howeve r, review of the lit erature by Findling e t al. ( 18) reveal s th at halop eridol has a lso been used in trea ting mood di sord ers, pervasive d evelopm ent al di sorder, m ent al ret a rd at ion, cond uct disord er, anorexia nervosa a nd person ality disorders in child re n a nd ado lesce nts. Children hav e been found to respond to lowe r neurol eptic plasm a levels ( 19) a nd th e dosing of haloperidol, in th e pedi atri c population , tends to be lowe r and more conse rva tive than in ad u lts . The average optim al dose range of halop e rid ol for th e sch izophre nic ped iatric population is 0.02 to 0.12 mg/kg/day [0.5 to 3.5 rug/day] (20) .
The most com mon sho rt-te rm side effec ts of hal op eridol in chi ldren an d adolesce n ts a re se dation a nd ext ra pyra m idal sym pto ms (E PS) (2 1). EPS are ra re ly obs erved in pr esch ool-aged ch ild re n, but a re mo re com mo n in schoo l age a nd adolesc e nts (19) . The se da tion is do se-rel at ed a nd ca n be reli eved by a reducti on in dose (21) . Extrapyr amidal sym ptoms are not do se-d ep endent a nd a re sudde n in onse t (9). Most
EPS ca n be resolved with a reducti on in dose a nd/o r managem ent with a n ticholinergics (20) . Also, with s ho rt -term halop eridol use, th e possibility of neurolept ic mali gnant synd ro me (NIVlS) sho uld be co nside re d . NMS is a pote nt iall y fa tal co mplica tion that occ u rs at all ages a nd sta rts wit hin a few days of initiati ng neuroleptic treat m en t. Fortunately th e synd ro me is rare -0.4% to 0.5% of newly t rea ted patients (22) . Also of co nce rn, in critica lly ill adu lts, is a n association of prol on ga tion of th e QTc in te rva l (Q T int erval co r recte d for heart rat e) with t he possib ility of e nsuing tor sad es d e pointes (a polymorphou s ve nt ricula r tach ycardia) wit h in traven ou s butyroph en one th erapy (23, 24) . Lawren ce & Nas raway (23) recommen d e lec t roca rd iog ra m (E KG) monitoring in critically ill patients, with di scont inuation or redu ct ion of dose if th e QTc int e rval len gthen s by 25% or more ove r baseline. Ca rdiac conduc tion a bnor ma liti es asso ciated with butyrophenone ad m inist ra tion in child re n a nd ado lescents ha ve not been report ed in th e lit erature and the implication s of thi s possibl e adve rse effect are not known.
There has onl y been on e study revealed in our sea rc h th at address ed th e use of neurol eptics to treat delirium in child re n a nd ad olescents. Brown et al. (25) st udied th e use of haloperidol in 30 pedi atric burn pati ents to treat ag ita t ion a nd delirium . H ere th e short term use of haloperidol (lon gest peri od of treatment was three months) had a n in cid en ce of adve rse react ion s of 0.4 7% (a n e pisode of decr ea sed consc ious nes s and a n ep isode of hypot en sion a fte r 429 doses administ ered ). Th e mean do se of halop eridol used was 0.047 mglk g wit h th e mean nu mb e r of doses given at 14. The largest cum ula tive dose administ ered ove r a 24-hour period was 0.455 mglk g. The la rgest num be r of doses given ove r a 24-hour pe riod was six . With intraven ou s ad m inist ra tion of halop eridol, th e ons et of effec t was wit hin thirty minut es. They repo rted high er efficacy via t he int rave nou s rout e a nd fou nd no con t ra ind ica tions to us ing halop e rid ol to treat ag itatio n in child re n.
Droperidol
Droperidol is a no t he r butyroph en on e neuroleptic th a t has a lso been used succ ess fully to treat delirium in ad ults (26,2 7). It is ava ila b le for int ra m uscula r or intravenous administration (1 7). Compared to hal op e rid ol , it has a more rap id on set of action, is more se da ting a nd is more a p t to ca use hypot en sion (9, 26) . It s use to treat d elirium in th e pediatric population ha s not been report ed. Howeve r, droperi dol has been studied for th e managem ent of acute ag ita tion a nd aggression in child re n and adolesce n ts .Joshi e t a l. (28) report ed use of intramuscul a r d rop eridol in a child re n's inpatient unit to co nt ro l ext re me aggre ss ion a nd violent beh avior s. Ov er a period of three yea rs, twenty-six child re n (mean age 01'9. 14) received a one ti m e dose (exce pt two boys who were refract ory aft er 30 minut es a nd req uired anoth er dose) of drop eridol to induce sedat ion. The a mo u nt of drop eridol used , in th e child re n, was Th e e me rge nce of th e new a typ ica l a ntipsychot ics has a llowed a greater armamen t of pharmacological choices in treating many psychiatric co nd itions in chi ldr en. The new m edications have shown ben efit without so me of th e extrapyramidal sid e effec ts of th e conve ntional antipsychotics (29) (30) (31) . The atypical a n tipsychotics have been us ed in child re n and adolescents in case s of schizophreni a (32,33), a utism (34), a nd pe rvasive developmental disorder (35) .
Dosing regimens of t he a typi ca l antipsychotics in child re n a nd ado lescents vary in th e lit erat ure. Rispe ridone and olanzapine are on ly ad m iniste re d en terally. Risp e ridone was FD A a pproved in 1993 wit h a dosing range of 2 to 16 mg/d ay ( 17) . In child re n wit h psyc hot ic di sorde rs, t he opt imal clin ica l response was found a t a mea n da ily dose of 5.93 mg (32) . In au tism , respon se was with a m ean do se of 1.3 mg/d ay (34) . A st udy of chi ldre n a nd ado lescents with pervasive developmenta l disord er showe d im proveme nt of sym ptoms wit h a m ea n dose of 2.7 rug/day (35) . The FDA a pproved ola nzapine in 1996 wit h a dosing ra nge of 5 to 20 rug/day ( 17) . In adults, ola nzapi ne has been found to poss es a ntipsychotic properties with a n optimal dosin g range of 2.5 to 15 mg/d ay (30) . O lanzapine has not been exte nsively stud ied in child re n, however, a pilot study of child hood-onset schizophre nia showed efficacy at a mean dos e of 17.5 rug/day (36) . Also a study of child re n, adol escen ts a nd adults wit h pervasive d evelopmental disord ers showed clinica l improvem ent with a mean dose of 7.8 mg/day (37) .
The lit erature do es not do cument m an y shor t-te rm co nt ra ind ica tions of t he newer antipsychotics in child re n and adoles cents. Rispe ridone ha s been shown to ca use mi ld sedation and EPS in a popu lation of adol escents with schizophre nia, with th e exp re ssion of EPS inversely proportionate to th e rat e of titration of t he rispe ridon e (32) . There has been a case re port of olanzapine (dosed 7.5 mg/d ay ove r a two to three week period) indu cing mania in a six tee n year old mal e (38) . Also, as wit h th e typica l an tipsychotics, t h ere is a ris k of NMS in th e newer a n tipsychotics. Sh arma et al. (39) report of risperidone-in du ced NMS in an ad olescent mal e.
T here have been no syst ematic st udies of t he efficacy of treating delir ium in chi ld ren or ad ults with t he new atypical antipsychotics. However Sipahimalani a nd M asand (40) report of a sixty year old male and a fourte en yea r old mal e in whom d eli riu m was successfu lly t reated wit h low doses of risperidon c. The adol escen t resp onded to I mg of risp e rid on e a t bed time wit hout side effec ts.
ADJUNCT MEDICATIONS
T he a nt ipsychotic med ications are conside re d efficacious in treating deliriu m (4 1). Polyph a rm acy has be en discouraged in ch ild re n (42) . Also, iatrogeni c indu ced d elirium is co mmon. Howeve r a few medi cin es hav e been used to au gm ent a nt ipsychot ics in trea ti ng deli ri u m a nd th ere may be ca se s wh ere adjunctiv e m edi cin e is d eemed ap propriate .
populat ion, th e use of ha lop eridol with slow titration to a n efficacious dose would see m to be th e logica l first lin e approach in treating d elirium. If a d eli riou s child with ava ila b le intravenous access were hospitalized , th en in traven ou s rout e wou ld be recommend ed du e to the rapid on set of ac tion and th e lowe r incide nce of EPS. If th e child do es not a lready have intraven ou s access, clinician judge m e nt wou ld di ct at e if th e seve rity of symptoms of th e d elirium require rapid infu sion of med icin e. Th e need for EKG monitoring, with intraven ou s butyrophen on e neurolep tic adm inistration in child re n and adolesce n ts , is qu esti on abl e. H oweve r, we recom men d a conse rva tive approach with baseline EKG acq uisition followed by ca rdiac mon itoring or dai ly QTc int erval testing. If th e QTc int erval incr eases 25% ove r baseline, t hen t he ne urol eptic do se should be d iscontinued or lowe red . The clinical use of d rop eridol in chi ldren is not as well investigated com pa re d to ha lop eridol. Halop eridol has a lon ger history of use in th e ped ia t ric popu lation, however we conside r droperidol an adeq uat e a lte rn ative.
T he re has on ly been on e case report of an atypica l a ntipsycho tic (risperido ne) used for th e treatment of d elir ium in an adolescent. At ypical a n ti psyc ho tics have shown efficac y in t rea ting a number of psychiatric co nd itions in child re n and adolescents, wit h minimal short-te rm sid e effec ts . Controlled st udies of t he at ypical antipsychotics in treating delirium are warrant ed to es tablish th eir efficacy.
Thes e recommendation s a re based on ass u m ptions from ad ult popul ations a nd th e lim it ed data availabl e pert aining to child re n a nd ado lesc en ts . Th is prot ocol is not meant for adheren ce as a p rotocol prop osed from con trolled st udy; rat her it is proposed as templat e for furth er st udy a nd to suffice as ot he r tec hniqu es a nd managem ent are po stu lat ed. Th e lack of d at a a nd sys tema tic a na lysis in th e lit erat ure pertaining to th e treatment of delirium in child re n a nd ado lesc e nts dem onstra tes an ac ute need for st r uc t ure d research in this area.
